传染病,过敏和免疫媒介疾病数据资源:景观概述和子组评估
Darya Pokutnaya1, Lisa M Mayer2, Sydney Foote2
1Office of Data Science and Emerging Technologies, National Institute of Allergy and Infectious Diseases, Rockville, MD, United States of America. dasha.pokutnaya@nih.gov.
Journal of medical systems
|November 22, 2025
概括
研究人员现在可以找到19个适合国家卫生研究院数据管理和共享计划的传染病数据资源. 本研究确定了资源,并强调了有效的数据共享数据提交要求的挑战.
科学领域:
- 传染病研究传染病研究.
- 数据科学是数据科学.
- 生物信息学是一种生物信息学.
背景情况:
- 美国国立卫生研究院 (NIH) 的数据管理和共享 (DMS) 政策规定了授予资助申请的DMS计划.
- 研究人员面临的困难是确定合适的数据资源,以满足DMS政策要求.
- 国家过敏和传染病研究所 (NIAID) 旨在协助研究人员准备DMS计划.
研究的目的:
- 编制传染病,过敏和免疫媒介疾病 (IID) 数据资源的全面列表.
- 确定IID数据资源,以支持向NIH DMS计划提交数据.
- 描述这些IID数据资源的特征和提交要求.
主要方法:
- 审查了在线资源,并咨询了主题专家,以确定IID数据资源.
- 根据NIH的建议和最佳实践开发了一个调查问卷,以评估数据资源.
- 描述了58个IID数据资源,重点关注那些适合提交数据的资源.
主要成果:
- 确定了303个数据资源,其中58个专门关注IID数据,主要是"omics",临床和生物测试数据.
- 发现了19个适合提交数据的IID数据资源,对注册,批准和网络成员资格的要求各不相同.
- 大多数资源提供开放访问,元数据和分析工具,但在提交要求和数据管理实践中发现了不一致.
结论:
- 19个IID数据资源的子集适合研究人员准备NIH DMS计划.
- 在资源之间存在不一致的数据提交要求和数据管理实践方面的挑战.
- 提高数据资源的透明度和标准化对于有效的数据共享和研究人员支持至关重要.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
995
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
995
Allergic Drug Reactions
1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Allergic Reactions
31.9K
Overview
31.9K
Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Hypersensitivities
6.9K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
6.9K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K


